CERS
Cerus CorporationNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$545.00M
P/E Ratio
—
EPS
$-0.05
Beta
1.63
52W High
$3.15
52W Low
$1.15
50-Day MA
$2.00
200-Day MA
$1.79
Dividend Yield
—
Profit Margin
-4.41%
Forward P/E
—
PEG Ratio
0.00
About Cerus Corporation
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
Fundamentals
| Revenue (TTM) | $216.56M |
| Gross Profit (TTM) | $114.76M |
| EBITDA | $-1.71M |
| Operating Margin | -0.66% |
| Return on Equity | -15.40% |
| Return on Assets | -0.93% |
| Revenue/Share (TTM) | $1.13 |
| Book Value | $0.33 |
| Price-to-Book | 8.07 |
| Price-to-Sales (TTM) | 2.52 |
| EV/Revenue | 2.595 |
| EV/EBITDA | 1183.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 24.10% |
| Shares Outstanding | $200.37M |
| Float | $186.14M |
| % Insiders | 3.26% |
| % Institutions | 73.83% |
Historical Volatility
HV 10-Day
156.26%
HV 20-Day
111.64%
HV 30-Day
95.45%
HV 60-Day
90.07%
HV Rank
99.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($4.67 target)
2
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/5/2026